The estimated Net Worth of Harold H. Shlevin is at least $2.33 Million dollars as of 4 June 2019. Harold Shlevin owns over 8,706 units of Galectin Therapeutics Inc stock worth over $23,854 and over the last 12 years he sold GALT stock worth over $995,718. In addition, he makes $1,306,510 as Director at Galectin Therapeutics Inc.
Harold has made over 9 trades of the Galectin Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 8,706 units of GALT stock worth $11,927 on 4 June 2019.
The largest trade he's ever made was exercising 119,200 units of Galectin Therapeutics Inc stock on 31 May 2018 worth over $189,528. On average, Harold trades about 23,665 units every 93 days since 2012. As of 4 June 2019 he still owns at least 8,706 units of Galectin Therapeutics Inc stock.
You can see the complete history of Harold Shlevin stock trades at the bottom of the page.
Dr. Harold H. Shlevin M.D. Ph.D. serves as Director of the Company retired from being our President and Chief Executive Officer on September 2, 2020, a position he had held since June 14, 2018; however, Dr. Shlevin has entered into a consulting agreement with the Company. Dr. Shlevin previously served as our Chief Operating Officer and Secretary from October 1, 2012. Dr. Shlevin previously had been employed at the Georgia Institute of Technology’s Advanced Technology Development Center as Principle and Manager of bioscience commercialization efforts since November 2009, where he has assisted faculty in identifying technology worthy of commercialization, catalyzed formation of new start-up bioscience companies, and mentored new company management. From October 2008 to November 2009, he served as Head of Operations and Commercial Development for Altea Therapeutics Corporation, an advanced drug delivery company focused on the delivery of therapeutic levels of water-soluble biotherapeutics and small drugs through the skin. At Altea, he was responsible for pharmaceutical research and development, clinical research, regulatory affairs, engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. From July 2006 to September 2008, Dr. Shlevin served as the President and Chief Executive Officer of Tikvah Therapeutics, Inc., a start-up pharmaceutical enterprise focused on later-stage development of neuroscience therapeutics. From May 2000 to January 2006, he served as President and CEO of Solvay Pharmaceuticals, Inc. (US). In January 2006, he was promoted to a global senior Vice President role within Solvay Pharmaceuticals, SA and member of the Board of Solvay Pharmaceuticals, SA. Previously, Dr. Shlevin served on the Board of Directors of Cardiome Pharma Corporation (NASDAQ: CRME), now known as Correvio Pharma Corp. (NASDAQ: CORV) from 2004 to June 2016.
As the Director of Galectin Therapeutics Inc, the total compensation of Harold Shlevin at Galectin Therapeutics Inc is $1,306,510. There are no executives at Galectin Therapeutics Inc getting paid more.
Harold Shlevin is 71, he's been the Director of Galectin Therapeutics Inc since 2020. There are 4 older and 15 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.
Harold's mailing address filed with the SEC is C/O GALECTIN THERAPEUTICS INC, 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS, GA, 30071.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr, and Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: